Skip to Content

Bausch & Lomb Corp BLCO

Morningstar Rating
$14.72 +0.06 (0.41%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

BLCO is trading at a 73% premium.
Price
$14.72
Fair Value
$49.00
Uncertainty
High
1-Star Price
$58.78
5-Star Price
$55.20
Economic Moat
Kqrxppc
Capital Allocation
Vvwxmflp

Bulls Say, Bears Say

Bulls

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.

Bears

Bausch will face margin pressures from upcoming losses of exclusivity on its pharmaceuticals, and this might hinder its efforts to raise margins to a level comparable with that of its close competitors.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLCO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$14.66
Day Range
$14.52–14.72
52-Week Range
$13.16–21.23
Bid/Ask
$14.20 / $15.11
Market Cap
$5.17 Bil
Volume/Avg
303,260 / 459,500

Key Statistics

Price/Earnings (Normalized)
19.81
Price/Sales
1.20
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Value
Total Number of Employees
13,300

Competitors

Valuation

Metric
BLCO
AFX
COO
Price/Earnings (Normalized)
19.8122.4925.23
Price/Book Value
0.782.792.19
Price/Sales
1.202.834.60
Price/Cash Flow
19.7817.9918.68
Price/Earnings
BLCO
AFX
COO

Financial Strength

Metric
BLCO
AFX
COO
Quick Ratio
0.762.340.84
Current Ratio
1.703.511.95
Interest Coverage
0.3519.185.25
Quick Ratio
BLCO
AFX
COO

Profitability

Metric
BLCO
AFX
COO
Return on Assets (Normalized)
1.99%9.06%2.88%
Return on Equity (Normalized)
3.62%12.67%4.48%
Return on Invested Capital (Normalized)
4.10%11.05%4.10%
Return on Assets
BLCO
AFX
COO
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
NcsmngcnpjZmcqv$157.4 Bil
Becton Dickinson & Co
BDX
DblsrtscqBpsshl$65.8 Bil
Alcon Inc
ALC
SryqmdwRszfq$43.8 Bil
ResMed Inc
RMD
JlsskhxmpGbctww$28.6 Bil
Coloplast A/S ADR
CLPBY
JqwnwfzxyrYpj$27.7 Bil
West Pharmaceutical Services Inc
WST
DvtqncspmwVtnn$23.6 Bil
Baxter International Inc
BAX
QvkwmpckSqsgprr$17.8 Bil
Hologic Inc
HOLX
GvrnynjYlmzlw$17.3 Bil
The Cooper Companies Inc
COO
JtjljtzvXnkrlr$17.1 Bil
Teleflex Inc
TFX
KzlnySylqh$10.1 Bil

Sponsor Center